The Latest Advances in Managing Mitral Valve Disease

1. Estévez-Loureiro R, Franzen O, Winter R, et al. Echocardiographic and clinical outcomes of central versus non-central percutaneous edge-to-edge repair of degenerative mitral regurgitation [published online ahead of print September 4, 2013]. J Am Coll Cardiol. doi:10.1016/j.jacc.2013.05.093.

2. Paranskaya L, D'Ancona G, Bozdag-Turan I, et al. Percutaneous mitral valve repair with the MitraClip system: perioperative and 1-year follow-up results using standard or multiple clipping strategy. Catheter Cardiovasc Interv. 2013;81(7):1224-1231.

3. Bonow RO. Chronic mitral regurgitation and aortic regurgitation: have indications for surgery changed? J Am Coll Cardiol. 2013;61(7):693-701.

4. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2012;33(19):2451-2496.

5. Suri RM, Vanoverschelde JL, Grigioni F, et al. Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets. JAMA. 2013;310(6):609-616.

6. Pizarro R, Bazzino OO, Oberti PF, et al. Prospective validation of the prognostic usefulness of B-type natriuretic peptide in asymptomatic patients with chronic severe aortic regurgitation. J Am Coll Cardiol. 2011;58(16):1705-1714.

7. Pizarro R, Bazzino OO, Oberti PF. Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. J Am Coll Cardiol. 2009;54(12):1099-1106.

8. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. N Engl J Med. 2013;369(13):1206-1214.

Disclosure statements are available on the authors' profiles: